Rating Change
HC Wainwright & Co. reiterated its Buy rating on Crescent Biopharma, Inc. Common Stock (NASDAQ:CBIO) on October 19, 2026.
reiterateNASDAQ:CBIO
HC Wainwright & Co. Reiterates Buy Rating on Crescent Biopharma, Inc. Common Stock (CBIO)
HC Wainwright & Co. reiterated its Buy rating on Crescent Biopharma, Inc.
At publication ·
What changed
Crescent Biopharma, Inc. Common Stock (NASDAQ:CBIO) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $12.36
- Market capitalization
- $213.7M
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Crescent Biopharma (CBIO) on October 19, 2026.
Market Context
Crescent Biopharma, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $12.36 with a market capitalization of $213.7M. The stock has declined 2.0% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Crescent Biopharma, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Crescent Biopharma, Inc. Common Stock
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 14, 2026 | Wedbush | Outperform | N/A |
| Aug 27, 2026 | Wedbush | Outperform | N/A |
| Jun 01, 2026 | HC Wainwright & Co. | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View CBIO Stock Page
Frequently Asked Questions
What does the Buy rating mean for CBIO?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Crescent Biopharma, Inc. Common Stock (NASDAQ:CBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CBIO forecast page.